Mounjaro vs. Wegovy: Which Weight Loss Medication Works Better?

Two commonly discussed medications are Mounjaro (tirzepatide) and Wegovy (semaglutide). Both can help reduce body weight when combined with healthy eating habits and regular physical activity. However, their mechanisms and effectiveness differ.

Why Are Mounjaro and Wegovy Being Compared?

Mounjaro and Wegovy are injectable medications used in medical weight management.

A clinical study directly compared tirzepatide and semaglutide in adults with obesity who did not have type 2 diabetes.

The study aimed to determine which medication could produce greater weight loss and whether their side effects differed significantly.

Which Medication Is More Effective for Weight Loss?

The study found a noticeable difference in average weight reduction between the two medications.

• Mounjaro (tirzepatide): Participants lost nearly 20% of their initial body weight on average.

• Wegovy (semaglutide): Participants lost approximately 14% of their initial body weight on average.

Participants receiving tirzepatide also experienced an average waist circumference reduction approximately 5 centimeters greater than those receiving semaglutide.

These findings suggest that tirzepatide may provide greater weight loss than semaglutide in adults with obesity who meet the study's eligibility criteria.

However, individual results may vary depending on medical conditions, treatment response, and lifestyle habits.

How Do Mounjaro and Wegovy Work?

Although both medications help manage appetite and food intake, they act on different hormonal pathways.

Wegovy - GLP-1 Receptor Agonist

Wegovy contains semaglutide, which mimics the action of glucagon-like peptide-1 (GLP-1).

GLP-1 is a hormone released after eating that helps regulate appetite and signals feelings of fullness.

By activating GLP-1 receptors, Wegovy can:

• Reduce hunger.

• Increase feelings of fullness.

• Help decrease overall food intake.

Mounjaro - Dual GIP and GLP-1 Receptor Agonist

Mounjaro contains tirzepatide, which activates two hormone receptors:

• GLP-1 - Helps regulate appetite and promote fullness.

• GIP (glucose-dependent insulinotropic polypeptide) - Plays a role in blood sugar regulation and metabolic responses.

By acting on both pathways, tirzepatide may produce greater weight reduction than medications that target GLP-1 alone.

What Are the Side Effects of Mounjaro and Wegovy?

Both medications can cause similar gastrointestinal side effects.

Common symptoms include:

• Nausea.

• Constipation.

• Diarrhea.

In the comparative study, approximately 6% of participants receiving tirzepatide discontinued treatment because of adverse effects, compared with around 8% of those receiving semaglutide.

Although the discontinuation rates were relatively similar, individual tolerance may differ.

Both medications can also cause more serious adverse effects in some patients, making medical assessment and monitoring important.

What Are the Limitations of the Study?

While the results suggest that tirzepatide produces greater average weight loss, several limitations should be considered.

1. The Study Was Not Blinded

Participants knew which medication they were receiving.

This may have influenced certain behaviors or outcomes during the study.

2. Participants Had Specific BMI Requirements

The study included adults who had:

• A body mass index (BMI) of 30 or higher.

• A BMI of 27 or higher with at least one weight-related health condition.

Therefore, the results may not apply to individuals outside these groups.

3. Greater Weight Loss Does Not Automatically Mean Greater Cardiovascular Protection

Although tirzepatide produced greater average weight loss, the study did not establish that it reduces cardiovascular events more effectively than semaglutide.

Weight reduction may improve certain cardiovascular risk factors, but comparative cardiovascular benefits require separate clinical evidence.

Which Medication Should You Choose?

The appropriate medication depends on several individual factors, including:

• Current body weight and BMI.

• Existing health conditions.

• Previous treatment history.

• Ability to tolerate side effects.

• Treatment costs and accessibility.

• Medical recommendations.

For adults with obesity who do not have type 2 diabetes, tirzepatide may lead to greater average weight loss than semaglutide.

However, greater effectiveness in a clinical study does not necessarily mean that one medication is the best choice for every patient.

Both treatments should be considered alongside dietary changes, exercise, and professional medical supervision.

Conclusion

Mounjaro and Wegovy are medications that can support weight management in appropriate patients.

A direct comparative study found that tirzepatide produced nearly 20% average weight loss, compared with approximately 14% for semaglutide. Tirzepatide also resulted in a greater reduction in waist circumference.

However, both medications have potential side effects and require careful consideration of individual health conditions.

Choosing between Mounjaro and Wegovy should involve a healthcare professional who can evaluate the expected benefits, risks, and suitability of each treatment.

 

Reference :

Vidé Hospital Mounjaro vs. Wegovy: Which Weight Loss Medication Works Better?

ArokaGO Providers Vidé Hospital